Cargando…
Short bevacizumab infusion as an effective and safe treatment for colorectal cancer
Bevacizumab is a humanized monoclonal antibody that contains <10% murine protein. To prevent infusion-related hypersensitivity reactions (HSRs), the initial bevacizumab infusion is delivered for 90 min, the second for 60 min and subsequent doses for 30 min. Several previous studies have shown tha...
Autores principales: | Taira, Koichi, Okazaki, Shunsuke, Akiyoshi, Kohei, Machida, Hirohisa, Ikeya, Tetsuro, Kimura, Akie, Nakata, Akinobu, Nadatani, Yuji, Ohminami, Masaki, Fukunaga, Shusei, Otani, Koji, Hosomi, Shuhei, Tanaka, Fumio, Kamata, Noriko, Nagami, Yasuaki, Fujiwara, Yasuhiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353868/ https://www.ncbi.nlm.nih.gov/pubmed/35949896 http://dx.doi.org/10.3892/mco.2022.2572 |
Ejemplares similares
-
A Rare Case of Clival Metastasis in a Patient with Gastric Cancer
por: Yoshikawa-Kimura, Akie, et al.
Publicado: (2020) -
Effect of the Coronavirus Disease 2019 Lockdown on Lifestyle Factors in Japanese Patients with Inflammatory Bowel Disease
por: Nishida, Yu, et al.
Publicado: (2022) -
Psychological Stress Exacerbates Inflammation of the Ileum via the Corticotropin-Releasing Hormone-Mast Cell Axis in a Mouse Model of Eosinophilic Enteritis
por: Kanamori, Atsushi, et al.
Publicado: (2022) -
Acceptance of COVID-19 Vaccines among Patients with Inflammatory Bowel Disease in Japan
por: Nishida, Yu, et al.
Publicado: (2021) -
Impact of the COVID-19 Pandemic on the Lifestyle and Psychosocial Behavior of Patients with Inflammatory Bowel Diseases: A Narrative Review
por: Nishida, Yu, et al.
Publicado: (2023)